2-(azidomethyl)-6-(chloromethyl)pyridine | 628308-62-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(azidomethyl)-6-(chloromethyl)pyridine
• 英文别名: 2-(Azidomethyl)-6-(chloromethyl)pyridine
• CAS: 628308-62-3
• 化学式: C₇H₇ClN₄
• 分子量: 182.612
• InChiKey: QHSAAHNXZHIQDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  27.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(azidomethyl)-6-(chloromethyl)pyridine 在 palladium on activated charcoal 氢气 作用下， 生成 {tert-Butoxycarbonyl-[6-(tert-butoxycarbonylamino-methyl)-pyridin-2-ylmethyl]-amino}-acetic acid ethyl ester
  参考文献：
  名称：

  Toward Protein-Cleaving Catalytic Drugs: Artificial Protease Selective for Myoglobin

  摘要：

  A protein-cleaving catalyst highly selective for a disease-related protein can be used as a catalytic drug. As the first protein-cleaving catalyst selective for a protein substrate, a catalyst for myoglobin (Mb) was designed by attaching the Cu(II) or Co(III) complex of cyclen to a binding site searched by a combinatorial method using peptide nucleic acid monomers as building units. Various linkers were inserted between the catalytic Co(III) center and the binding site of the Mb-cleaving catalyst. Kinetic data revealed catalytic turnover of the Mb cleavage by the Cu(II) or Co(III) complex. MALDI-TOF MS revealed cleavage of the polypeptide backbone of Mb at selected positions. N-Terminal sequencing of the cleavage products identified the cleavage site and provided evidence for the hydrolytic nature of the Mb cleavage. Various chelating ligands were tested as the ligand for the Co(III) center of the Mb-cleaving catalyst. Among the nine chelating ligands examined, only cyclen and its triaza-monooxo analogue manifested catalytic activity. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00216-5
• 作为产物：
  描述：

  2,6-二氯甲基吡啶 在 sodium azide 、 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-(azidomethyl)-6-(chloromethyl)pyridine
  参考文献：
  名称：

  [EN] AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
  [FR] COMPOSÉS AMINOPYRAZINES AYANT DES PROPRIÉTÉS ANTAGONISTES DE L'A2A

  摘要：

  公开的是Formula A和Formula A-1的化合物，或其盐，以及包含这些化合物或其盐的药物配方（药物组合物）；其中“R1”、“RA-1”、“R2”、“R3”和“Het”如上所定义，这些化合物被认为适用于选择性拮抗A2a受体，例如，在基底神经节中高密度存在的受体。这些化合物和药物配方被认为在治疗或管理神经退行性疾病方面有用，例如帕金森病，或由于使用治疗或管理帕金森病的某些药物而引起的运动障碍。

  公开号：

  WO2016081290A1

文献信息

• Ruthenium complexes featuring cooperative phosphine–pyridine–iminophosphorane (PNN) ligands: synthesis, reactivity and catalytic activity
  作者：Thibault Cheisson、Louis Mazaud、Audrey Auffrant

  DOI：10.1039/c8dt03488e

  日期：——

  of two isomers. The complexes [RuLRHCl(PPh3)] were similarly obtained from [RuHCl(PPh3)3]. The stability of these complexes depends on the ligand substitution pattern; with LPh a CH activation process took place, while [RuLCyHCl(PPh3)] was thermally stable. Deprotonation of this latter complex was achieved and gave a catalytically competent species for the acceptorless dehydrogenative coupling of alcohols

  两个膦-吡啶-亚氨基正膦配体L R（PPh 2 CH 2（C 6 H 3 N）CH 2 N PR 3，R = Ph或Cy）与钌（II）中心的配位因取代基的性质不同而不同探索了P N磷。与[RuCl 2（PPh 3）3 ]配位得到[Ru L R Cl 2（PPh 3）]配合物，其在酸性膦基甲基位置成功地去质子化。与L Cy，配位导致两种异构体的混合。类似地从[RuHCl（PPh 3）3 ]获得配合物[Ru L R HCl（PPh 3）]。这些配合物的稳定性取决于配体的取代方式。用L Ph进行CH活化过程，而[Ru L Cy HCl（PPh 3）]是热稳定的。实现了后一种配合物的去质子化，并给出了用于醇的无受体脱氢偶联的催化活性物质。
• Palladium(<scp>ii</scp>) complexes featuring a mixed phosphine–pyridine–iminophosphorane pincer ligand: synthesis and reactivity
  作者：Thibault Cheisson、Audrey Auffrant

  DOI：10.1039/c5dt02789f

  日期：——

  methane. Neutral complexes with the deprotonated ligand such as 3 yielded in the presence of deuterated methanol the corresponding deuterated complex, showing that the protonation is reversible with this ligand. Finally, upon attempting to dealkylate complex 4 using B(C6F5)3, an unexpected zwitterionic borated complex 5, resulting from the formation of a C–B bond in the benzylic position with restoration

  合成了原始的式PPh 2 -CH 2 -Pyr-CH 2 -N PPh 3的混合配体（标记为L），结合了吡啶核与膦和亚氨基正膦。研究了其与钯（II）中心的配合。用[Pd（COD）Cl 2 ]，获得阳离子络合物[ L PdCl]（Cl）1，其中L以钳位模式配位。在吡啶存在下用银盐提取氯化物可生成双阳离子络合物[ L Pd（py）]（BF 4）2（2）。当与诸如六甲基二硅氮烷钾（KHMDS）之类的碱反应时，得到1的中性络合物3 [ L * PdCl]，其中α-膦的苄基位置被选择性去质子化，从而诱导吡啶环脱芳香化。[Pd（CH 3）2（TMEDA）]和L通过甲烷的离开而反应，得到类似的络合物[ L * Pd（CH 3）]（4）。具有去质子化配体的中性配合物，例如3在存在氘代甲醇的情况下得到相应的氘代配合物，表明该配体的质子化是可逆的。最后，在尝试使用B（C 6 F 5）3使配合物4脱烷基化时，意
• Halogen Bonding Tripodal Metallo‐Receptors for Phosphate Recognition and Sensing in Aqueous‐Containing Organic Media
  作者：Hena Bagha、Robert Hein、Jason Y. C. Lim、Christopher B. Durr、Mark R. Sambrook、Paul D. Beer

  DOI：10.1002/chem.202302775

  日期：2024.1.8

  taining halogen bonding (XB) tripodal ZnII metallo-receptors, strategically designed for tetrahedral anion guest binding, are demonstrated to selectively recognise inorganic phosphate over more basic, mono-charged oxoanions and the halides in aqueous solvent media. The XB metallo-receptors display augmented anion affinities compared to their tris(prototriazole)-containing hydrogen bonding (HB) counterparts

  一系列含三（碘三唑）卤素键 (XB) 三足 Zn II金属受体，专门为四面体阴离子客体结合而设计，被证明能够选择性识别无机磷酸盐，而不是碱性更强的单电荷含氧阴离子和水性溶剂中的卤化物媒体。与含三原三唑的氢键 (HB) 对应物相比，XB 金属受体表现出增强的阴离子亲和力。 XB 和 HB 三足受体末端氧化还原活性二茂铁部分的附着促进了互补的电化学阴离子传感能力。
• Aminopyrazine compounds with A2A antagonist properties
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10472347B2

  公开（公告）日：2019-11-12

  Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein “R1”, “RA-1”, “R2”, “R3”, and “Het” are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

  公开了式A和式A-1化合物或其盐，以及包含这些化合物或其盐的药物制剂（药物组合物）；其中 "R1"、"RA-1"、"R2"、"R3 "和 "Het "如上文所定义，这些化合物被认为适用于选择性拮抗A2a受体，例如，在基底神经节中高密度存在的A2a受体。 此类化合物和药物制剂被认为可用于治疗或控制神经退行性疾病，例如帕金森病，或因使用某些用于治疗或控制帕金森病的药物而引起的运动障碍。
• AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3220910A1

  公开（公告）日：2017-09-27